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A 4½-year-old girl presented with an incompletely resected, huge, immature 
abdominal teratoma, elevated serum alpha-fetoprotein (AFP), and numerous mil-
iary gliomatosis peritonei (GP). Two courses of chemotherapy resulted in normali-
zation of her AFP level and marked tumor shrinkage. Further chemotherapy was 
interrupted by complications. During treatment for these complications, ascites 
increased and the tumor enlarged, but serum AFP remained within the normal 
range. Second-look surgery revealed that the tumor had changed histologically to a 
mature teratoma, and GP had enlarged to nodular size, causing massive ascites. 
The still incompletely resected, growing mature teratoma was reduced with inter-
feron. Nodular GP and ascites slowly regressed with interferon use, and finally dis-
appeared after several months. One residual mass thought to be GP was reduced by 
gamma-knife surgery 3 years later.
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1. Introduction
Immature teratomas (IMT) in children are poten-
tially malignant, especially when they present with 
elevated levels of alpha-fetoprotein (AFP) or human 
chorionic gonadotropin (hCG).1 Chemotherapy is nec-
essary in such situations.1−3 Histologic grading seems 
less predictive than tumor markers in children.1 
Chemotherapy changes the features of IMT to those 
characteristic of mature teratomas (MT), and re-
duces levels of tumor markers.3−5 Curiously, however, 
the tumor mass sometimes increases in size while 
tumor marker levels decrease,3,6−9 and further 
chemotherapy is unable to shrink this growing tumor. 
Here we report a case, initially diagnosed as IMT 
and associated with elevated AFP, which changed to 
growing teratoma syndrome (GTS) after two courses 
of chemotherapy, and was then stabilized with in-
terferon. The gliomatosis peritonei (GP) was miliary 
in size at the first surgical examination, but had 
increased to nodular size at second-look surgery, 
after cessation of chemotherapy. The GP and ascites 
eventually regressed.
2. Case Report
This 4½-year-old girl was diagnosed with a grade 3 
IMT, 13 × 15 × 14 cm in size, originating from the left 
ovary and containing neuroepithelium and glial tissue. 
Growing teratoma syndrome 79
Numerous miliary foci of glial implants, known as GP, 
each < 0.5 mm in diameter, were detected over the 
omentum and lower pelvic wall. Ascites of 170 cm3 
was noted. Maximal tumor removal was performed 
leaving residual tumor at the base where it adhered 
tightly to the retroperitoneum. The GP were too 
numerous to remove, and were only biopsied. Be-
cause of an elevated serum AFP level of 4222 ng/
mL, the patient received chemotherapy with ifos-
famide 1.2 g/m2 for one dose, mesna 1.2 g/m2 for one 
dose, cisplatin 20 mg/m2/day for 5 days, and etopo-
side 75 mg/m2/day for 5 days. The patient subse-
quently developed severe neutropenic infection, 
acute renal failure, and persistent hyponatremia 
lasting for a period of 8 months. The second course 
of chemotherapy consisted of cyclophosphamide 
1g/m2 for one dose and epirubicin 30 mg/m2/day for 
2 days. The patient subsequently developed Legionella 
pneumonia and carditis with acute congestive heart 
failure.
After the two courses of chemotherapy, the 
tumor shrank considerably and AFP levels fell, but 
the tumor failed to continue to shrink after nor-
malization of AFP. In contrast, the ascites and tumor 
volumes progressively increased (Figure 1). Second-
look surgery revealed many nodular GP, each > 0.5 cm 
in diameter, 2700 cm3 ascites, and an enlarged, 
incompletely-excised main tumor with gross resid-
uals. Histopathologic examination revealed that the 
main tumor had changed to a MT. Interferon α-2b 
3 MIU/m2 three times per week was given for 
9 months, but was then stopped due to neurological 
complications. The size of the original main tumor 
was reduced during and after interferon treatment, 
without recurrence.
Slow regression of GP and ascites also occurred 
during and after interferon treatment. Three years 
after stabilization of a 1.5 × 2.3-cm diameter sub-
phrenic residual mass supposed to be residual GP 
(Figure 2), which could not be removed during second-
look surgery, the patient underwent gamma-knife 
surgery to remove the mass. She remained free of 
disease 2 years after radiation therapy and 5 years 
after stopping interferon.
3. Discussion
IMT with elevated AFP often behaves in a malignant 
fashion, because small foci of malignant germ cell 
elements in the tumor can be easily overlooked in 
pathological specimens.6 Chemotherapy is necessary 
in such situations.1−3
Post-chemotherapy residual masses undergo his-
tological changes into MT.3−5 Chemotherapy is inef-
fective against MT.1,6 Curiously, teratomas are often 
observed to increase in size during or after chemo-
therapy, as tumor marker levels decrease.3,6−9 This is 
known as GTS, a situation first described by Logothetis 
et al in 1982.7 According to Logothetis, three criteria 
are required to define GTS: normalization of previ-
ously elevated serum tumor markers (AFP or hCG), 
Figure 1 Multiple gliomatosis peritonei nodules over the 
peritoneum, mesentery and subdiaphragm area, massive 
ascites, and the main mass of the growing mature teratoma 
over the lower abdomen.
Figure 2 A 1.5 × 2.3-cm diameter lobulated mass over 
the esophageal-gastric junction. Regression of ascites and 
multiple nodular gliomatosis peritonei.
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an increase in tumor size during or after chemo-
therapy given for non-seminomatous germ cell tumor 
(NSGCT), and an absence of any NSGCT components, 
other than MT, at tumor resection.
GTS is characterized by an absence of malignant 
germ cell components, indicating that the growing 
tissues are benign, and not partially treated NSGCT 
remaining after previous chemotherapy.10 Further 
chemotherapy is unable to shrink GTS, but interferon 
can control disseminated, unresectable MT or GTS, 
as in the current case.11−14 Interferon inhibits tumor 
angiogenesis mediated by decreased levels of vascu-
lar endothelial growth factor and basic fibroblast 
growth factor.15−17
GP is a rare disease, first described in 1906 and 
defined as peritoneal implantations of mature glial 
tissue in patients with ovarian teratomas of any 
grade.18,19 At least 86 cases of GP with teratoma have 
been reported.20 IMT, MT, and GTS have all been 
reported in association with GP,10,21−25 but there has 
been no report of any case with a combination of 
all these conditions, GTS responsive to interferon, 
and GP growing from miliary to nodular size. Waiting, 
or complete surgical excision, is the usual treatment 
for GP.24,25 Our patient had numerous miliary GP at 
initial diagnosis, while nodular GP, which could not be 
excised completely, were found during second-look 
surgery. The responsiveness of GP to chemotherapy 
remains controversial,20 and no mention has been 
made of the use of interferon to treat GP. However, 
a common origin has been suggested for GP, MT and 
GTS.10,20 Miliary GP did not enlarge during chemo-
therapy in our patient, suggesting some inhibitory 
effect of chemotherapy. However, the GP enlarged 
to nodular size after cessation of chemotherapy in 
accord with GTS. In our patient, the slow regression 
of ascites and nodular GP during interferon treat-
ment, originally aimed at GTS, is not sufficient to 
indicate interferon efficacy. Further studies are 
needed to determine a possible role for interferon 
therapy.
The outcome of GP is not always benign, as re-
ported by Shefren et al, who described an adolescent 
who presented more than 5 years after diagnosis 
with a malignant, abdominal glial neoplasm, pre-
sumably representing a malignant transformation of 
mature gliomatosis.26 Although our patient remained 
free of disease 5 years after interferon therapy and 
2 years after radiation therapy, regular follow up 
continues to be necessary.
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